Randomized Trialhigh evidence
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Nature medicine·November 1, 2023·PMID 37840095
Why it mattersThis trial demonstrates that adding tirzepatide after initial lifestyle-induced weight loss can nearly double total weight reduction, offering a potent sequential strategy for obesity management. It provides high-quality evidence for specialists considering pharmacotherapy following behavioral interventions.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled